Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 3/20 | 0.34 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
| ▸ | KRAS | P01116 | 2/20 | 0.32 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.32 |
| ▸ | HTR3B | O95264 | 1/20 | 0.32 |
| ▸ | HTR3A | P46098 | 1/20 | 0.32 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.32 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.32 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.31 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.31 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.31 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.31 |
| ▸ | KDM1A | O60341 | 1/20 | 0.31 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.31 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6100564 | 0.90 | KDM1A (0.37) | CHRNA7IRAK4SLC6A2SLC6A4CHRNB2 | |
| SCHEMBL6099436 | 0.87 | IRAK4 (0.38) | CHRNA7IRAK4SLC6A4SLC6A3CHRNB2 | |
| SCHEMBL6099441 | 0.85 | IRAK4 (0.36) | CHRNA7IRAK4SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL6100264 | 0.83 | CHRNA7 (0.34) | CHRNA7IRAK4HTR3EHTR3BHTR3A | |
| SCHEMBL6101467 | 0.83 | SLC6A2 (0.34) | CHRNA7SLC6A2SLC6A4SLC6A3CHRNB4 | |
| SCHEMBL6100142 | 0.82 | CHRNA7 (0.32) | CHRNA7USP30 | |
| SCHEMBL6101149 | 0.82 | HCRTR1 (0.39) | CHRNA7SLC6A2SLC6A4SLC6A3KDM1A | |
| SCHEMBL5917815 | 0.82 | CHRNA7 (0.48) | CHRNA7HTR3EHTR3BHTR3AHTR3D | |
| Hydrochloric Acid SCHEMBL5231652 | 0.81 | CHRNA7 (0.47) | CHRNA7HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL6100743 | 0.81 | SLC6A2 (0.34) | SLC6A2SLC6A4SLC6A3HTR3ACHRNB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030236270-A1 | Azabicyclic compounds for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-12-25 | — | — | US | claimed |
| US-7001900-B2 | Azabicyclic compounds for the treatment of disease | PFIZER INC. (US) | 2006-02-21 | — | — | US | disclosed |
| US-20030236270-A1 | Azabicyclic compounds for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236270-A1 | Azabicyclic compounds for the treatment of disease | MALT1, TPMT, CYP2B6 | CHRNA7 1836/4885IRAK4 3560/4885SLC6A2 1361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.